Johnson & Johnson (JNJ) news

Older JNJ news events, each with the realized, point-in-time move the market made — page 10 of 10. Back to the JNJ overview → · Full JNJ reaction history →

Latest news

Recent JNJ events, each with its measured reaction. (Page 10 of 10.)

DateHeadlineEventSource5-minTo close
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%Press releaseBusiness Wire+1.19%+0.31%
Johnson & Johnson Reports Q1 2024 ResultsPress releaseBusiness Wire+1.19%+0.31%
Signature Resolution Welcomes Hon. Eddie C. Sturgeon (Ret.) to Panel of NeutralsPress releasePR Web-0.13%-0.65%
Engel & Völkers Continues Franchise Expansion in Florida with New Location in TrinityPress releasePR Web+0.14%-0.26%
Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare ConferencePress releaseBusiness Wire-0.13%+0.49%
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of TherapyPress releasePR Newswire+0.14%-0.26%
Johnson & Johnson to Acquire Shockwave MedicalPress releaseBusiness Wire+0.14%+0.24%
Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment CorporationPress releaseBusiness Wire+0.14%+0.24%
Companies are paying $500 per hour to people who participate in focus groupsPress releasePR Web-0.03%+0.59%
Johnson & Johnson to Participate in the BofA Securities Health Care ConferencePress releaseBusiness Wire-0.26%-2.24%
Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE™ Platform for the Treatment of Paroxysmal Atrial FibrillationPress releasePR Newswire-0.01%-0.12%
The Next Great Biotech Boom Has ArrivedPress releasePR Newswire-0.43%-0.29%
Form ARS JOHNSON & JOHNSON For: Dec 31SEC filing · Form ARSSEC EDGAR-1.19%-0.88%
Form DEF 14A JOHNSON & JOHNSON For: Apr 25SEC filing · Form DEFSEC EDGAR-1.19%-0.88%
Form DEFA14A JOHNSON & JOHNSONSEC filing · Form DEFA14ASEC EDGAR-1.19%-0.88%
Johnson & Johnson to Host Investor Conference Call on First-Quarter ResultsPress releaseBusiness Wire+0.55%+1.00%
Johnson & Johnson Completes Acquisition of AmbrxPress releaseBusiness Wire-0.03%-0.71%
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsPress releasePR Newswire+0.03%+0.03%
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myelomaPress releasePR Newswire-0.26%+0.42%
Form 10-K JOHNSON & JOHNSON For: Dec 31SEC filing · Form 10-KSEC EDGAR+0.12%+0.67%
Form 13F-HR JOHNSON & JOHNSON For: Dec 31SEC filing · Form 13F-HRSEC EDGAR-0.10%-0.23%
Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare ConferencePress releaseBusiness Wire+0.81%+1.24%
Johnson & Johnson to Participate in the Leerink Global Biopharma ConferencePress releaseBusiness Wire+0.44%-0.74%
Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF SymposiumPress releasePR Newswire-0.69%-0.52%
Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors ConferencePress releaseBusiness Wire-0.69%-0.52%
Form 8-K JOHNSON & JOHNSON For: Jan 23SEC filing · Form 8-KSEC EDGAR-0.59%-0.12%
Johnson & Johnson Reports Q4 and Full-Year 2023 ResultsPress releaseBusiness Wire-0.59%-0.12%
Biosense Webster Announces Regulatory Approval of VARIPULSE™ Pulsed Field Ablation (PFA) Platform in JapanPress releasePR Newswire+0.19%+0.00%
Form DEFA14A JOHNSON & JOHNSONSEC filing · Form DEFA14ASEC EDGAR-0.28%+0.15%
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of CancerPress releaseBusiness Wire-0.28%+0.15%
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2024Press releaseBusiness Wire+0.44%+1.94%
Key Talc Lawyers: Planned “Prepack” J&J Bankruptcy is “Farce” and Improper Litigation TacticPress releaseBusiness Wire-0.73%+1.39%
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter ResultsPress releaseBusiness Wire-0.45%+0.04%
Johnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare ConferencePress releaseBusiness Wire-0.42%-0.81%
Form 8-K JOHNSON & JOHNSON For: Dec 05SEC filing · Form 8-KSEC EDGAR+0.46%-0.16%
Form 8-K JOHNSON & JOHNSON For: Nov 30SEC filing · Form 8-KSEC EDGAR-0.40%-1.20%
Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business ReviewPress releaseBusiness Wire+0.46%-0.16%
Publication in Bloomberg Law: ‘A Third J&J Bankruptcy Attempt Won’t Resolve Victims’ Talc Claims’ by Andy BirchfieldPress releaseBusiness Wire-0.12%+0.03%
Form 8-K JOHNSON & JOHNSON For: Nov 30SEC filing · Form 8-KSEC EDGAR-0.18%+1.24%
Johnson & Johnson MedTech Acquires Laminar, Inc.Press releaseBusiness Wire-0.16%+1.58%
Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of DirectorsPress releaseBusiness Wire-0.18%+1.24%
Form 8-K JOHNSON & JOHNSON For: Nov 21SEC filing · Form 8-KSEC EDGAR-0.13%+0.15%
Talc Lawyer: Johnson & Johnson Settlements Undermine Bankruptcy Strategy, Serve as Acknowledgment That Baby Powder Contained AsbestosPress releaseBusiness Wire+0.01%+0.19%
Johnson & Johnson to Host Enterprise Business ReviewPress releaseBusiness Wire-0.05%+0.40%
Ethicon Introduces ETHIZIA™ Hemostatic Sealing Patch, Clinically Proven to Stop Disruptive BleedingPress releasePR Newswire+0.16%+0.92%
Form 13F-HR JOHNSON & JOHNSON For: Sep 30SEC filing · Form 13F-HRSEC EDGAR-0.26%-0.68%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground